Going Beyond Antibiotics! Developing First-In-Class

New Post Public Reply Private Reply Replies (0) Message Board
crookedneck

Going Beyond Antibiotics!

Developing First-In-Class Anti-Infectives 
to Fight Bacteria, Viruses and Fungi

Corporate Profile

ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds.  Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body’s defense against infection.  They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
  
NOVABAY’S FOUR BUSINESS UNITS

NovaBay is focusing its technology on four distinct therapeutic areas:  dermatology, ophthalmology, urology and hospital infections.  In dermatology, the focus is on developing NVC-422 gel for impetigo and acne.  NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world.  In ophthalmology, the company anticipates continuing its development of NVC-422 for the treatment of adenoviral conjunctivitis to confirm the encouraging results shown for epidemic keratoconjunctivitis (EKC) seen in the adenoviral conjunctivitis trial. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422.  In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration.

COLLABORATION WITH GALDERMA

NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. 

News and Features  

February 9, 2012
NovaBay Pharmaceuticals Provides Business Update and 2012 Outlook

Archive of Conference Call
 Click Here To Listen

February 8, 2012
NovaBay Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

February 7, 2012
NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-end Business Update and 2012 Outlook

January 23, 2012
NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422

January 9, 2012
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China

November 30, 2011
NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program

November 14, 2011
NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future

November 7, 2011
NovaBay Pharmaceuticals Reports Third Quarter Financial Results

October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 4, 2011
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. As Head of Ophthalmic Drug Development

September 28, 2011
NovaBay Pharmaceuticals Names Russell A. Hoon As Vice President of its Advanced Wound Care Business Unit

September 21, 2011
NovaBay Pharmaceuticals to Present at the LD MICRO Invitational Conference

September 12, 2011
NovaBay Pharmaceuticals Reports Positive Results in Sinus Infection Study

August 25, 2011
NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today

August 24, 2011
NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference

August 10, 2011
NovaBay Pharmaceuticals Reports Second Quarter Financial Results

July 11, 2011
NovaBay Pharmaceuticals Provides Business Update

July 5, 2011
NovaBay Pharmaceuticals Announces the Closing of its $5.2 Million Registered Direct Offering of Common Stock and Warrants

June, 29 2011
NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants

June, 16, 2011
NovaBay Regains Worldwide Rights to Its Aganocide Compounds from Alcon

May 23, 2011
NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24

May 18, 2011
Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
 Click Here To Listen

May 18, 2011
NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis

May 16, 2011
NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results

May 6, 2011
NovaBay Pharmaceuticals Spotlights Three New Aganocide Compounds with Confirmed Activity against Ophthalmic Pathogens

April 19, 2011
NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase Study of 26 Patients With Chronic Non-Healing Wounds

April 14, 2011
NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference

April 12, 2011
NovaBay Pharmaceuticals Spotlights Positive Results for Its Novel Anti-Infective at 2011 Simon Foundation for Continence Conference

March 28, 2011
Archive of Conference call Re: Business and Clinical Developments from NovaBay's Four Business Units
 Click Here To Listen

March 10, 2011
NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2010 Financial Results and Business Unit Updates

March 9, 2011
NovaBay Pharmaceuticals to Present at the Roth Capital 23rd Annual Growth Stock Conference on March 16

March 2, 2011
NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter Blockage and Encrustation

February 18, 2011
NovaBay Pharmaceuticals Ranked No. 7 in Biotech Industry in Fast Company's Annual List of World's Most Innovative Companies

February 8, 2011
NovaBay Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

February 2, 2011
NovaBay Pharmaceuticals Provides Summary of 2010 Accomplishments and 2011 Outlook

January 7, 2011
NovaBay Pharmaceuticals to Present at 2011 Biotech Showcase Conference

January 6, 2011
NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly "Superbug" producing NDM-1 (New Delhi Metallo-beta-lactamase-1)

December 16, 2010
NovaBay Pharmaceuticals CEO Contributes Article to The Scientist

December 6, 2010
NovaBay Pharmaceuticals and Galderma Expand Their Agreement to Include Impetigo

Novabay Pharmaceuticals (NBY) Stock Research Links

NBY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading